Breast cancer drug Nerlynx can be prescribed in general hospitals. According to related industries, the oral tyrosine kinase inhibitor Nerlynx, which inhibits Bixink Therapy's HER2 protein, passed the Drug Committee (DC) of the Big 5 Advanced General Hospital, including Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, and Sinchon Severance Hospital.

However, as it is still a non-reimbursed drug, it is expected to take some time until the prescription is reimbursed. This drug was submitted to the Health Insurance Review and Assessment Service in February, but it was judged that the benefit standard was not set. Bixink Therapetics plans to submit it again in the second half